Methylation Diet and Lifestyle Study

NCT03472820 | Active Not Recruiting

• 1 other identifier: RB100217
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

The maintenance of health and the progression of disease are associated with an individual's genetic make-up and environmental factors, including lifestyle choices (such as diet, exercise, behaviors, stressors, sleep, tobacco and alcohol use), environmental exposures and socioeconomic determinants. Environmental factors have been shown to influence, sometimes rapidly, epigenetic processes thereby influencing genetic expression. Regulation of the human genome by the epigenome is now regarded as a cornerstone, heritable, physiologic process, playing a key role in phenotypic expression of health and disease. DNA methylation is a well-researched, primary epigenetic process. Aberrant DNA methylation resulting in hyper- or hypomethylated regions of the genome, generally results in inhibition or expression of certain genes and has been associated with the pathogenesis of numerous conditions, ranging from inflammation and accelerated aging, to cancer, autoimmunity, diabetes, heart disease, dementia, allergic disease, posttraumatic stress disease and others. Likewise, certain healthy diet and lifestyle habits have been demonstrated to favorably influence DNA methylation patterns. Understanding that environmental factors can potently and sometimes rapidly, favorably or negatively influence epigenetic expression, a short-term diet and lifestyle intervention may significantly augment DNA methylation expression. The purpose of this study is to evaluate a 9-week diet and lifestyle intervention on patient-reported quality of life, symptoms, and DNA and biochemical methylation-related biomarkers in healthy males ages 50-72.

Conditions

Lifestyle; Diet; Healthy

Keywords

Diet; Lifestyle; DNA methylation

Outcome Measures

Primary Outcomes (1)

• Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29)

  PROMIS-29 will measure health-related quality of life and is a validated, 29 question survey divided into seven sub-domains of function including physical functioning, social function, pain interference, pain intensity, sleep, depression, and anxiety.

  8 weeks

Secondary Outcomes (2)

• Measure Yourself Medical Outcome Profile (MYMOP)

  8 weeks

• National University of Natural Medicine Multi-system Symptom/Adverse Event Questionnaire

  8 weeks

Other Outcomes (5)

• Infinium Methylation EPIC Index by Illumina

  8 weeks

• Methylation Profile by Doctor's Data

  8 weeks

• Folate Vitamer Panel by Doctor's Data

  8 weeks

Study Arms (2)

Intervention Group

EXPERIMENTAL

The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.

Other: Diet Recommendations; Other: Lifestyle Recommendations; Other: Exercise Recommendations; Other: Stress Management Recommendations; Other: PhytoGanix (tropical fruit flavor); Other: UltraFlora Intensive Care

Control Group

NO INTERVENTION

The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.

Interventions

Diet Recommendations OTHER

Specific dietary guidelines will be outlined for participants.

Intervention Group

Lifestyle Recommendations OTHER

Participants are encouraged to average a minimum of 7 hours of sleep per night.

Intervention Group

Exercise Recommendations OTHER

Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.

Intervention Group

Stress Management Recommendations OTHER

Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.

Intervention Group

PhytoGanix (tropical fruit flavor) OTHER

Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.

Intervention Group

UltraFlora Intensive Care OTHER

Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.

Intervention Group

Eligibility Criteria

• Age: 50 Years - 72 Years
• Gender Eligibility Details: Male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males, ages 50-72
• Willing to adhere to 9 weeks of a dietary and lifestyle program including specific nutrition and exercise guidelines
• Willing to avoid any over-the-counter medications, supplements or herbal products for the length of the study, except short-term use (\<1 week) use at least 1 week before scheduled study visits
• Willing to have blood drawn three times and abstain from food or beverage intake for 10-12 hours before blood draws
• Willing to provide saliva samples
• Willing to track food intake, sleep, stress management techniques, and exercise daily
• Willing to drink a nutrient-enriched beverage and take a encapsulated probiotic daily
• Willing and able to use electronic devices and connect to the internet
• Able to speak, read and understand English

You may not qualify if:

• Currently taking any of the following prescription medications
• Proton pump inhibitors: omeprazole (Prilosec, Prilosec OTC); aspirin and omeprazole (Yosprala); lansoprazole (Prevacid, Prevacid IV, Prevacid 24-Hour); ;dexlansoprazole (Dexilent, Dexilent Solutab); rabeprazole (Aciphex, Aciphex Sprinkle); pantoprazole (Protonix)
• H2-blockers: nizatidine (Axid, Axid AR, Axid Pulvules); famotidine (Pepcid, Pepcid AC); cimetidine (Tagamet, Tagamet HB); ranitidine (Zantac)
• These classes of medications are excluded due to direct (due to nutrient requirements for metabolism) and indirect (through impaired digestion and assimilation of nutrients).
• Use of nutrition supplements or herbal products not prescribed by a licensed healthcare provider for a medical condition
• Currently following a prescribed dietary/lifestyle program or initiate within the 30 days prior to baseline
• Initiation of or changes to an exercise regimen within 30 days prior to baseline
• Use of nicotine, marijuana or cannabinoids (including CBD products) or recreational drugs/substances (such as but not limited to cocaine, phencyclidine \[PCP\], and methamphetamine) current/within the last 30 days or use during the study
• Have a diagnosis of cardiovascular disease, kidney disease, liver disease, diabetes, autoimmune disease, high blood pressure, or cancer (does not include basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix).
• Have a diagnosis of an immunodeficiency condition, such as Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
• Have a diagnosis of neurodegenerative conditions such as, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Multiple Sclerosis, or Alzheimer's disease.
• Excessive alcohol consumption (more than 4 drinks per day or 14 per week on average)
• Known sensitivity, intolerance or allergy to ingredients in the study supplements or in the recommended dietary therapy
• Currently receiving intravenous nutrient therapy
• Currently participating in another interventional research study or participated in another interventional study within the last 3 weeks prior to baseline

Sponsors & Collaborators

• National University of Natural Medicine: lead
• Dr. Kara Fitzgerald, ND: collaborator
• Metagenics, Inc.: collaborator

Study Sites (1)

NUNM Helfgott Research Institute

Portland, Oregon, 97201, United States

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 22, 2018
• First Posted: March 21, 2018
• Study Start: February 1, 2018
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2024
• Last Updated: August 6, 2024

Record last verified: 2024-08

Locations

US (1)